<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7397">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00929201</url>
  </required_header>
  <id_info>
    <org_study_id>0431A-080</org_study_id>
    <secondary_id>MK-0431A-080</secondary_id>
    <secondary_id>2009_607</secondary_id>
    <nct_id>NCT00929201</nct_id>
  </id_info>
  <brief_title>Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)</brief_title>
  <official_title>An Open-Label, Randomized, Two-Period Crossover Definitive Bioequivalence Study With the Final Marketed Image (FMI) Sitagliptin/Metformin Fixed-Dose Combination (FDC) Tablet and Co-Administration of the Sitagliptin and Metformin Individual Tablets After Consumption of a High-Fat Meal in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will demonstrate the bioequivalence of metformin after single dose administration
      of sitagliptin/metformin 50/500 mg fixed dose combination (FDC) tablet and concomitant
      administration of single doses of sitagliptin 50 mg and metformin 500 mg as individual
      tablets after consumption of a high-fat meal.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Plasma Area Under the Curve (AUC(0 to Infinity)) for Metformin</measure>
    <time_frame>Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum samples were used to determine the AUC from time 0 to infinity for metformin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of Metformin</measure>
    <time_frame>Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum samples were used to determine the maximum concentration for metformin.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sita + Met then Sita/Met FDC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive sitagliptin (Sita) 50 mg and metformin (Met) 500 mg individual tablets administered concomitantly as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin/metformin (Sita/Met) 50/500 mg FDC tablet administered as a single dose during Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sita/Met FDC then Sita + Met</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive sitagliptin/Metformin 50 mg/500 mg FDC tablet administered as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose during Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin phosphate/metformin hydrochloride FDC</intervention_name>
    <description>Single dose sitagliptin/metformin 50/500 mg FDC tablet after consumption of a high-fat meal in one of two treatment periods.</description>
    <arm_group_label>Sita + Met then Sita/Met FDC</arm_group_label>
    <arm_group_label>Sita/Met FDC then Sita + Met</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin phosphate</intervention_name>
    <description>Single dose sitagliptin 50 mg tablet after consumption of a high-fat meal in one of two treatment periods.</description>
    <arm_group_label>Sita + Met then Sita/Met FDC</arm_group_label>
    <arm_group_label>Sita/Met FDC then Sita + Met</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin hydrochloride</intervention_name>
    <description>Single dose metformin 500 mg tablet after consumption of a high-fat meal in one of two treatment periods.</description>
    <arm_group_label>Sita + Met then Sita/Met FDC</arm_group_label>
    <arm_group_label>Sita/Met FDC then Sita + Met</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  is in good health

          -  is a nonsmoker

          -  is willing to follow all study guidelines

        Exclusion Criteria:

          -  has or has a history of any illness or condition that might confound the results of
             the study or make participation unsafe for the participant

          -  is a nursing mother

          -  is unwilling to consume the required high-fat breakfast
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 22, 2015</lastchanged_date>
  <firstreceived_date>June 25, 2009</firstreceived_date>
  <firstreceived_results_date>January 5, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sita + Met Then Sita/Met FDC</title>
          <description>Sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin/metformin (Sita/Met) 50/500 mg fixed-dose combination (FDC) tablet administered as a single dose during Period 2.</description>
        </group>
        <group group_id="P2">
          <title>Sita/Met FDC Then Sita + Met</title>
          <description>Sitagliptin/Metformin 50 mg/500 mg FDC tablet administered as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose during Period 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>7-day Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All randomized participants</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="61"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="32.4" lower_limit="18" upper_limit="45"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="32"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Centimeters</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="164.9" lower_limit="150.0" upper_limit="184.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="73.0" lower_limit="45.9" upper_limit="102.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Area Under the Curve (AUC(0 to Infinity)) for Metformin</title>
        <description>Serum samples were used to determine the AUC from time 0 to infinity for metformin.</description>
        <time_frame>Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours postdose</time_frame>
        <safety_issue>No</safety_issue>
        <population>All participants who completed and who had pharmacokinetic data available from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Sita + Met</title>
            <description>Sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose</description>
          </group>
          <group group_id="O2">
            <title>Sita/Met FDC</title>
            <description>Sitagliptin/Metformin 50 mg/500 mg final marketed image (FMI) FDC tablet administered as a single dose</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Plasma Area Under the Curve (AUC(0 to Infinity)) for Metformin</title>
            <description>Serum samples were used to determine the AUC from time 0 to infinity for metformin.</description>
            <units>μg * hr/mL</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7.65" spread="1.39"/>
                  <measurement group_id="O2" value="7.45" spread="1.48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least-Squares Mean Ratio calculated as Sitagliptin/Metformin 50/500 mg FDC tablet divided by Sitagliptin 50 mg and metformin 500 mg individual tablets</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The FMI sitagliptin/metformin 50/500 mg FDC tablet and coadministration of corresponding doses of sitagliptin and metformin as individual tablets after consumption of a standard high-fat breakfast will be bioequivalent for metformin based on assessment of the AUC0-∞ for metformin [i.e., the true metformin AUC0-∞GMR (sitagliptin/metformin 50/500 mg FDC tablet/co-administration of sitagliptin and metformin as individual tablets will be contained within (0.80, 1.25)].</non_inferiority_desc>
            <param_type>Least-Squares Mean Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Plasma Concentration (Cmax) of Metformin</title>
        <description>Serum samples were used to determine the maximum concentration for metformin.</description>
        <time_frame>Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours postdose</time_frame>
        <safety_issue>No</safety_issue>
        <population>All participants who completed and who had pharmacokinetic data available from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Sita + Met</title>
            <description>Sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose</description>
          </group>
          <group group_id="O2">
            <title>Sita/Met FDC</title>
            <description>Sitagliptin/Metformin 50 mg/500 mg FMI FDC tablet administered as a single dose</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Peak Plasma Concentration (Cmax) of Metformin</title>
            <description>Serum samples were used to determine the maximum concentration for metformin.</description>
            <units>ng/mL</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="929" spread="181"/>
                  <measurement group_id="O2" value="887" spread="187"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least-Squares Mean Ratio calculated as Sitagliptin/Metformin 50/500 mg FDC tablet divided by Sitagliptin 50 mg and metformin 500 mg individual tablets</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The FMI sitagliptin/metformin 50/500 mg FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets after consumption of a standard high-fat breakfast will be bioequivalent for metformin based on assessment of the Cmax for metformin [i.e., the true metformin Cmax GMR (sitagliptin/metformin 50/500 mg FDC tablet/ co-administration of sitagliptin and metformin as individual tablets will be contained within (0.80, 1.25)].</non_inferiority_desc>
            <param_type>Least-Squares Mean Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 24 days (including 14 days after administration of study drug in the last treatment period)</time_frame>
      <desc>All participants as treated defined as all participants who received at least one dose of study drug</desc>
      <group_list>
        <group group_id="E1">
          <title>Sita + Met</title>
          <description>Sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose</description>
        </group>
        <group group_id="E2">
          <title>Sita/Met FDC</title>
          <description>Sitagliptin/Metformin 50 mg/500 mg FMI FDC tablet administered as a single dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
